Cipla gets final approval for Albuterol Sulfate Inhalation Aerosol

09 Apr 2020 Evaluate

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation, from the United States Food and Drug Administration (USFDA).

The company’s Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation, is the first AB-rated generic therapeutic equivalent version of Merck Sharp & Dohme Corp’s Proventil HFA Inhalation Aerosol. It is used for treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1318.55 -9.70 (-0.73%)
29-Jan-2026 13:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1599.40
Dr. Reddys Lab 1201.45
Cipla 1318.55
Zydus Lifesciences 887.55
Lupin 2120.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×